Instil Bio, Inc.
No SEC Form 4 filings for $TIL in the last 30 days.
See all $TIL insider activity →Instil Bio, Inc. (TIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q2-26er.htm EX-99.1 Document Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update DALLAS, TX, August 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing in
Instil Bio, Inc. (TIL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. til-20260611 FALSE 0001789769 0001789769 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
TIL Limited (NSE: TIL) reported Q4FY26 and full-year FY26 results. FY26 revenue was Rs. 337.36 Cr vs Rs. 343.07 Cr in FY25, with machine sales up 4% to Rs. 265.33 Cr. The company cited lower other income and financing/currency and one-time settlement expenses. It won major orders (including Rs. 66.75 Cr CONCOR ReachStackers) and approved a majority-stake acquisition of Tulip Compression (completed May 2026) to enter LNG/hydrogen powerpacks and related manufacturing.
Over the past 7 days, alphai's AI scored 1 news story mentioning TIL (Instil Bio, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent TIL coverage spans financial news, earnings and corporate actions.
The filing updates Instil’s cash runway and operating expense trajectory, which can drive near-term valuation and financing expectations.
Routine corporate governance disclosure; no new operating/financial guidance or material transaction is described.
Earnings print plus a new clean-energy manufacturing vertical (TCPL) and re-entry into higher-margin O&M should re-rate forward earnings mix if execution holds.
The article indicates a bearish sentiment for TIL with weak price momentum, suggesting potential downside in the near term.
The investigation into Instil Bio, Inc. (TIL) following a significant stock decline suggests potential downside risk in the near term.
alphai scores every news story that mentions TIL with an AI model for sentiment and relevance, and aggregates insider trades from Instil Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Instil Bio, Inc. (TIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q2-26er.htm EX-99.1 Document Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update DALLAS, TX, August 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing in
5 min readInstil Bio, Inc. (TIL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. til-20260611 FALSE 0001789769 0001789769 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
2 min readTIL Limited (NSE: TIL) reported Q4FY26 and full-year FY26 results. FY26 revenue was Rs. 337.36 Cr vs Rs. 343.07 Cr in FY25, with machine sales up 4% to Rs. 265.33 Cr. The company cited lower other income and financing/currency and one-time settlement expenses. It won major orders (including Rs. 66.75 Cr CONCOR ReachStackers) and approved a majority-stake acquisition of Tulip Compression (completed May 2026) to enter LNG/hydrogen powerpacks and related manufacturing.
6 min readThis article provides a price-driven insight for Instil Bio Inc. (NYSE: TIL) from Stock Traders Daily, indicating weak sentiment across all horizons and supporting a short bias. It details institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis, and information on accessing real-time AI-generated signals.
5 min readBronstein, Gewirtz & Grossman, LLC has initiated an investigation into Instil Bio, Inc. (NASDAQ:TIL) on behalf of investors following a significant stock price drop. The investigation comes after Instil's subsidiary, Axion Bio, Inc., announced the discontinuation of clinical development for AXN-2510 and the termination of a related licensing agreement, which led to Instil's shares falling by over 45%. The law firm encourages affected investors to seek additional information and assist with the investigation.
2 min readInstil Bio's subsidiary, Axion Bio, has discontinued clinical development of AXN-2510 and terminated its license and collaboration agreement with ImmuneOnco for AXN-2510 and AXN-27M. This decision leads to all rights for AXN-2510 outside Greater China reverting to ImmuneOnco, with Axion retaining a limited license to wind down existing clinical activities. This marks a significant shift from previous updates which highlighted AXN-2510 as a key clinical asset, prompting investors to focus on Instil Bio's reallocation of R&D resources and future pipeline developments.
2 min readThis article, despite its title, primarily narrates a fictional story about a female police officer named Zhao Younan who investigates a large seizure of methamphetamine in the town of Sanping. The text describes her relentless pursuit of a chemical drug trafficker named Huang Zongwei, highlighting a game of cat and mouse filled with intelligence and bravery. The actual stock-related content on Instil Bio Inc. is superficial and seems to be a template for promotional snippets rather than a substantive analysis.
2 min readUS phase 1 trial of '2510 is expected to be initiated before the end of ...
2 min readDoes Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out.
2 min readThe mean of analysts' price targets for Instil Bio (TIL) points to a 246.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
3 min read
